REVOLUTION MEDICINES, INC. : BERNSTEIN RAISES TARGET PRICE TO $179 FROM $151
Bernstein has increased its target price for Revolution Medicines, Inc. (RVMD.O) to $179 from $151. This update, reported by Reuters, indicates a positive reevaluation of the company's stock outlook by the analyst firm.
Enterprise value to revenue forward of Revolution Medicines, Inc. – NASDAQ:RVMDW
This article provides financial data for Revolution Medicines, Inc. (NASDAQ:RVMDW), specifically focusing on its enterprise value to revenue forward. It appears to be a financial snapshot from TradingView, displaying key company information.
Revolution Medicines (RVMD) Is Up 5.1% After Offloading Phase 3 Costs to BeOne Medicines
Revolution Medicines (RVMD) saw a 5.1% stock increase after partnering with BeOne Medicines. This collaboration shifts the financial burden of a global Phase 3 study for one of Revolution's RAS(ON) inhibitors to BeOne, while also granting BeOne regional commercialization rights in certain Asian markets. Despite this positive development, Revolution Medicines continues to face significant losses, emphasizing the need for their late-stage programs to gain approval and generate revenue.
Price to book forward of Revolution Medicines, Inc. – NASDAQ:RVMDW
This article displays a financial metric, "Price to book forward," for Revolution Medicines, Inc. (NASDAQ: RVMDW). The content primarily serves as a placeholder for financial data, indicating that there are no active trades or specific values to show at the time of publication, suggesting a focus on providing real-time financial information when available.
Is Revolution Medicines (RVMD) Fully Valued After Its BeOne Collaboration Deal?
Revolution Medicines (RVMD) has gained investor attention due to a recent collaboration with BeOne Medicines, covering joint clinical studies on RAS(ON) inhibitors and exclusive development rights for BeOne in certain Asian markets. Despite strong share price momentum and a "Most Popular Narrative" suggesting RVMD is 4% overvalued at $212, Simply Wall St's DCF model indicates a deep undervaluation, with a fair value of $723.76 per share. The article highlights the contrasting valuation perspectives and advises investors to consider the underlying data and risks, such as heavy cash use and a concentrated therapeutic focus.
Why Revolution Medicines (RVMD) Stock Is Up Today
Revolution Medicines (RVMD) stock rose 5.5% today, primarily driven by continued investor optimism after the U.S. FDA accepted its new drug application for daraxonrasib, a treatment for previously treated metastatic pancreatic cancer. The positive movement is further supported by recent bullish analyst commentary and ongoing advancements in the company's broader RAS-targeted pipeline, suggesting a momentum-driven gain.
Revolution Medicines stock hits all-time high at 208.77 USD
Revolution Medicines Inc. (RVMD) stock reached an all-time high of $208.77, currently trading at $208.48, reflecting a remarkable 468.97% increase over the past year. Despite being considered overvalued by InvestingPro analysis, the company closed Q2 with $3.9 billion in cash and investments and is advancing late-stage programs in pancreatic and lung cancer, leading Guggenheim to raise its price target to $240.
State of Wyoming Buys Shares of 9,446 Revolution Medicines, Inc. $RVMD
The State of Wyoming recently acquired 9,446 shares of Revolution Medicines, Inc. (NASDAQ:RVMD) valued at approximately $1.77 million, marking a new position in the biopharmaceutical company. This move comes as institutional investors and hedge funds collectively hold 94.34% of RVMD's stock. Despite a recent earnings miss, analysts maintain a "Moderate Buy" rating for Revolution Medicines, although the consensus price target is currently below the stock's reported trading price.
S&CO Inc. Invests $6.40 Million in Revolution Medicines, Inc. $RVMD
S&CO Inc. recently invested $6.4 million in Revolution Medicines, Inc. (NASDAQ:RVMD) by purchasing 34,171 shares, contributing to institutional ownership of 94.34%. Despite a larger-than-expected quarterly loss, analysts maintain a "Moderate Buy" rating with a consensus price target of $161.79. Insider transactions show mixed activity, with significant stock sales by directors totaling over $21 million in the last 90 days.
Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?
BeOne Medicines AG and Revolution Medicines, Inc. have announced a clinical collaboration and licensing deal aimed at developing combination therapies for RAS-addicted cancers. This partnership is seen as a win-win, with BeOne leveraging its commercial strength and Asian market infrastructure, while Revolution gains non-dilutive capital and expanded clinical trial execution for its promising RAS-targeted portfolio. The collaboration addresses financial strengths and weaknesses of both companies, with BeOne being profitable and Revolution a pre-revenue biotech, and has garnered varied interest from hedge funds.
Baker Bros. Advisors (RVMD) discloses 11.4M-share position in Revolution Medicines
Baker Bros. Advisors LP and related entities have reported a passive ownership stake of 5.3% in Revolution Medicines, Inc. This translates to beneficial ownership of 11,443,357 shares of common stock, held through investment funds Baker Brothers Life Sciences, L.P. and 667, L.P. The filing indicates that Baker Bros. Advisors maintains sole voting and dispositive power over these shares.
Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?
BeOne Medicines AG and Revolution Medicines, Inc. have announced a clinical collaboration and licensing deal focused on RAS-addicted cancers. BeOne, a commercially strong company, will acquire exclusive rights in select Asian markets and fund a Phase 3 trial, while Revolution, a pre-revenue biotech, gains non-dilutive capital and execution scale. The partnership leverages BeOne's financial strength and Asian infrastructure with Revolution's pipeline of RAS(ON) inhibitors, presenting a synergistic opportunity for both.
Farallon funds disclose 13.6M-share RVMD stake in Schedule 13G/A filing
Farallon Capital Management, L.L.C. and its affiliated funds have disclosed a beneficial ownership of 13,564,149 shares, or 6.4%, of Revolution Medicines, Inc. (RVMD) common stock, according to a recent Schedule 13G/A filing. This includes 13,550,796 shares and 120,085 common stock purchase warrants, with the warrants subject to a 9.99% beneficial ownership limitation. Farallon Capital Management and several managing members share voting and dispositive power over these securities, with dividends and sale proceeds going to the Farallon Funds.
Revolution Medicines (RVMD): Janus Henderson discloses 5.1% beneficial stake
Janus Henderson Group Ltd. has disclosed a 5.1% beneficial ownership stake in Revolution Medicines, Inc. (RVMD), holding 10,736,145 shares of common stock. These shares are managed across various client portfolios, with Janus Henderson exercising shared voting and dispositive power but disclaiming economic ownership, which belongs to the individual managed portfolios. No single managed portfolio holds more than five percent of Revolution Medicines' common stock.
Handelsbanken Fonder AB Raises Stock Position in Revolution Medicines, Inc. $RVMD
Handelsbanken Fonder AB significantly increased its stake in Revolution Medicines, Inc. (NASDAQ:RVMD) by 243.6% in the second quarter, bringing its total holdings to 212,275 shares valued at $39.8 million. Despite institutional investors owning a substantial 94.34% of the company, Revolution Medicines reported a quarterly loss that missed consensus estimates, and analysts anticipate a full-year loss of $8.65 per share. The stock opened near its 52-week high, with a "Moderate Buy" consensus rating and an average price target of $161.79, although company insiders have recently sold a considerable amount of shares.
Why Revolution Medicines May Be Big Pharma’s Next Takeover Target
Revolution Medicines (NASDAQ:RVMD) is highlighted as a potential acquisition target for big pharma due to its strong late-stage RAS(ON) oncology pipeline, particularly daraxonrasib's impressive pancreatic cancer data. Merck (NYSE:MRK) is identified as the most likely acquirer, driven by the impending patent cliff for its drug Keytruda and its stated goal of diversifying its growth portfolio. Other plausible acquirers include Pfizer, Johnson & Johnson, Bristol Myers Squibb, and Roche, but Merck has the strongest motive and means.
Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest.
Revolution Medicines has achieved a $44.1 billion market cap, driven by its promising RAS-targeting oncology pipeline, despite having no current product revenue. The company's drug, daraxonrasib, has shown strong clinical results, particularly in improving survival for pancreatic cancer patients. This success makes Revolution Medicines a potential acquisition target for major pharmaceutical companies like Merck, Roche, and Bristol Myers Squibb, given the scarcity of advanced RAS therapies.
Revolution Medicines (RVMD) Stock Looks Strong On Returns But Expensive On Value
Revolution Medicines (RVMD) has shown strong long-term returns, with its stock price increasing 7x over the past five years and 483% in the last year. However, Simply Wall St's analysis suggests the stock is currently overvalued, particularly based on its P/B ratio which is significantly higher than industry averages. The company's future performance hinges on its oncology pipeline, including RAS(ON) programs, and its ability to justify the high premium investors are paying despite current losses.
Revolution Medicines (RVMD) Stock Looks Strong On Returns But Expensive On Value
Revolution Medicines (RVMD) has shown strong shareholder returns over the past five years, but its current valuation appears expensive based on broader checks. The stock trades at a high Price-to-Book ratio compared to its industry and peers, suggesting it may be overvalued despite excitement around its pipeline. Investors need to consider if the oncology pipeline can justify the current premium or if the price already assumes too much future success.
Tema ETFs LLC Sells 26,443 Shares of Revolution Medicines, Inc. $RVMD
Tema ETFs LLC has reduced its stake in Revolution Medicines, Inc. by 26.9%, selling 26,443 shares but still retaining 71,735 shares valued at $13.4 million. Despite this, institutional investors collectively own 94.34% of the company, and analyst sentiment remains largely positive with a "Moderate Buy" consensus rating. Recent insider transactions show significant selling activity, with insiders selling 132,497 shares worth approximately $21.5 million over the past 90 days.
BeOne Medicines Enters Collaboration with Revolution Medicines for Oncology Therapies
BeOne Medicines and Revolution Medicines have announced a multi-part collaboration to evaluate drug combinations for RAS-addicted cancers and extend the geographic footprint of Revolution Medicines' therapies. The deal includes a clinical collaboration for combination studies using BeOne's oncology assets and Revolution's four RAS(ON) inhibitors, along with a regional rights agreement for select Asian markets. BeOne will fund a global Phase III study and Revolution Medicines will receive development and sales milestone payments, plus tiered royalties.
Bank of America Corp DE Cuts Holdings in Revolution Medicines, Inc. $RVMD
Bank of America Corp DE reduced its stake in Revolution Medicines, Inc. by 30.2% in Q1 2026, selling 265,688 shares and retaining 614,157 shares valued at $59.7 million. Despite this, institutional investors own 94.34% of the company, and Wall Street analysts generally maintain a "Moderate Buy" rating with an average price target of $160.68. The company recently reported a quarterly loss of $3.06 per share, missing estimates, and insiders have sold shares worth approximately $21.5 million in the past 90 days.
Revolution Medicines (RVMD) BeOne Deal Puts Its Valuation Back In Focus
Revolution Medicines (RVMD) recently announced a collaboration with BeOne Medicines, impacting its stock valuation. While analysts set a consensus price target slightly below the current share price at $204.38, Simply Wall St's DCF model suggests a deep undervaluation at $721.01. The article highlights the conflicting valuations and potential risks associated with the company, such as heavy cash use and trial outcomes.
BeOne and Revolution Medicines partner on RAS(ON) inhibitor combinations in Asia
BeOne Medicines and Revolution Medicines have formed a two-part partnership concerning RAS(ON) inhibitors in select Asian markets. The agreement includes clinical combination studies and regional commercialization rights for Revolution Medicines' four clinical-stage RAS(ON) inhibitors. BeOne will also fund and conduct a global registrational Phase III study for one of the inhibitors and gain exclusive development and commercialization rights in the specified territories.
BeOne Medicines and Revolution Medicines Partner on RAS(ON) Cancer Therapies
BeOne Medicines and Revolution Medicines have announced a collaboration to advance targeted therapies for RAS-addicted cancers. This partnership includes both clinical development of new treatment combinations and a regional commercialization agreement in Asia. The companies aim to explore combinations of BeOne's oncology candidates with Revolution Medicines' clinical-stage RAS(ON) inhibitors and expand access to these therapies globally.
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
BeOne Medicines and Revolution Medicines have announced a multi-part collaboration focusing on clinical development and regional commercialization. The collaboration includes evaluating drug combinations of BeOne's oncology assets with Revolution Medicines' four clinical RAS(ON) inhibitors for RAS-addicted cancers, and a regional rights agreement granting BeOne exclusive development and commercialization rights to these inhibitors in select Asian markets. BeOne will also fund and conduct a global registrational Phase 3 study for one of Revolution Medicines' RAS(ON) inhibitors.
Why Revolution Medicines (RVMD) Is Up 9.4% After Mounting Losses And Surging Daraxonrasib Demand – And What's Next
Revolution Medicines (RVMD) reported increased net losses in Q2 2026 but saw its stock rise 9.4% due to the FDA's acceptance of daraxonrasib's New Drug Application for metastatic pancreatic cancer and high compassionate use demand. Over 2,000 patients have already received daraxonrasib, highlighting its real-world need ahead of potential approval. The company's future hinges on the commercial success of its RAS(ON) pipeline, with analysts projecting significant revenue and earnings by 2029 if daraxonrasib is approved.
Assenagon Asset Management S.A. Buys Shares of 200,486 Revolution Medicines, Inc. $RVMD
Assenagon Asset Management S.A. recently acquired a new position in Revolution Medicines, Inc. (NASDAQ:RVMD), purchasing 200,486 shares valued at approximately $37.55 million in the second quarter. This move makes Assenagon Asset Management S.A. the owner of 0.09% of Revolution Medicines' stock. Other institutional investors and hedge funds also adjusted their holdings, with several buying new positions or increasing their stakes, bringing institutional ownership of RVMD to 94.34%.
Why Revolution Medicines (RVMD) Is Up 9.4% After Mounting Losses And Surging Daraxonrasib Demand – And What's Next
Revolution Medicines (RVMD) is experiencing a 9.4% stock increase despite mounting losses, driven by the advancement of its drug daraxonrasib through FDA review for metastatic pancreatic cancer. The drug has seen significant demand, with over 2,000 patients receiving it through compassionate use even before potential approval. The company faces ongoing high cash burn and losses but has a strong cash balance and positive Phase 3 data for daraxonrasib, which analysts project could lead to substantial revenue and earnings by 2029.
Why Revolution Medicines (RVMD) Is Up 9.4% After Mounting Losses And Surging Daraxonrasib Demand – And What's Next
Revolution Medicines (RVMD) reported a significant net loss in Q2 2026, yet its stock rose by 9.4% due to advancing daraxonrasib through FDA review for metastatic pancreatic cancer and high compassionate use demand. Over 2,000 patients have received daraxonrasib, indicating strong real-world interest, and the company has a substantial cash balance to support its pipeline. The focus now is on potential FDA approval, which could reshape its investment narrative despite ongoing losses and high cash burn.
'We're excited and ready to go': Fast-growing Revolution Medicines preps potential launch of blockbuster pancreatic cancer drug
Revolution Medicines is preparing for the potential launch of its pancreatic cancer drug, daraxonrasib. The Redwood City-based company, led by CEO Mark Goldsmith, boasts a substantial financial reserve of $3.9 billion in cash and equivalents, positioning it strongly among mid-size biotechs for this significant development.
Revolution Medicines, Inc. Stock 12‑Month Price Target Raised to $216.4, Implies 10% Upside
Revolution Medicines, Inc. (RVMD) has seen its average price target raised from $207.16 to $216.4 by 20 analysts, with forecasts ranging from $151 to $263 per share. This updated target suggests a potential 10% upside based on the Aug. 5 closing price. The consensus rating for RVMD remains "Buy" among 21 covering analysts.
Revolution Medicines, Inc. Stock 12‑Month Price Target Raised to $215.71, Implies 9% Upside
Revolution Medicines, Inc. (RVMD) has seen its average 12-month price target increase from $207.16 to $216.4, according to 20 analysts. This updated target implies a 10% potential upside from its Aug. 5 closing price. The consensus rating for RVMD remains "Buy" among 21 covering analysts.
Quantinno Capital Management LP Boosts Stake in Revolution Medicines, Inc. $RVMD
Quantinno Capital Management LP significantly increased its stake in Revolution Medicines (RVMD) by 97.6% in the first quarter, now owning 63,360 shares valued at $6.16 million. Despite the company reporting a wider-than-expected quarterly loss of $3.06 per share, institutional investors hold 94.34% of the stock, and analysts maintain a "Moderate Buy" rating with an average price target of $144.67. Insider selling also occurred, with executives selling shares worth approximately $21.5 million during the quarter.
Earnings call transcript: Revolution Medicines lifts spending outlook in Q2 2026
Revolution Medicines ended Q2 2026 with $3.9 billion in cash and investments and increased its 2026 spending forecast to $2.1 billion to $2.2 billion to advance late-stage oncology programs and prepare for a potential first product launch. The company's lead drug, daraxonrasib, cleared a key regulatory hurdle with the FDA accepting its NDA for pancreatic cancer review, and commercial infrastructure is largely in place for a U.S. launch. Despite rising net losses due to increased R&D and administrative expenses, the stock remains near its 52-week high, indicating investor focus on the pipeline and future commercialization.
Revolution Medicines Q2 Net Loss Widens
Revolution Medicines reported a significant widening of its net loss in Q2, increasing to $111.4 million from $70.8 million year-over-year, largely due to increased research and development expenses. Despite the loss, the company exceeded revenue expectations with $9.3 million, up from $2.1 million in the prior year, driven by collaboration revenue. Revolution Medicines ended the quarter with $910.6 million in cash, cash equivalents, and marketable securities.
Revolution Medicines falls on second quarter earnings miss
Revolution Medicines (NASDAQ:RVMD) reported a significant earnings miss for the second quarter, with a loss of -$3.06 per share against an estimated -$1.96. The net loss for the quarter reached $644.4 million, impacted by a non-cash charge related to an acquisition. Despite the financial miss, the company highlighted the progress of its drug daraxonrasib, including the FDA's acceptance of its New Drug Application for metastatic pancreatic cancer.
Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings
Revolution Medicines, Inc. (RVMD) reported its Q2 2026 earnings, missing EPS estimates by 48.8% due to a significant non-cash warrant charge. Despite being a pre-revenue company, RVMD has substantial cash reserves to fund its first commercial launch, with upcoming catalysts including Phase 3 RASolve 307 data and updated colorectal data. The FDA also accepted its pancreatic cancer application for daraxonrasib.
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Revolution Medicines announced its Q2 2026 financial results and provided an update on corporate progress, highlighting the FDA's acceptance of daraxonrasib's New Drug Application for metastatic pancreatic cancer and the rapid implementation of an Expanded Access Program. The company also reported encouraging new combination data for daraxonrasib, zoldonrasib, and elironrasib in lung cancer, supporting future registrational studies, and updated its full-year operating expense guidance.
Revolution Medicines, Inc. Q2 2026: Net loss $(644.4M), EPS $(3.06) — 10-Q Summary
Revolution Medicines, Inc. (RVMD) reported a net loss of $(644.4M) for Q2 2026, an increase from $(247.8M) in Q2 2025, primarily due to higher R&D and pre-launch commercial investments. The company's cash and equivalents totaled $3.9B, providing over 12 months of liquidity. Key business highlights include FDA acceptance of daraxonrasib's NDA, expansion of clinical trials, and strategic partnerships.
Revolution Medicines stock hits all-time high of 195.48 USD By Investing.com
Revolution Medicines Inc. (RVMD) has reached an all-time stock high of $195.48, reflecting significant investor confidence with a 1-year price return of 403.93%. Despite an InvestingPro analysis suggesting the stock is overvalued, analysts from UBS, Mizuho, Wedbush, and Truist Securities have raised price targets or maintained "Buy" ratings, citing promising clinical data and regulatory progress. The company's market capitalization has grown to $41.14 billion, indicating strong market belief in its biotechnology advancements.
Is Revolution Medicines (RVMD) Fully Valued Following Its FDA Filing Win?
Revolution Medicines (RVMD) has seen significant stock price appreciation after its New Drug Application for daraxonrasib was accepted by the FDA for metastatic pancreatic cancer. Despite a 137.32% year-to-date rise, Simply Wall St's narrative suggests RVMD is still undervalued by 8.2% with a fair value of $204.38, driven by its promising RAS(ON) oncology pipeline. However, the company faces risks due to heavy cash usage, no current revenue, and potential trial disappointments or delays.
Is Revolution Medicines (RVMD) Fully Valued Following Its FDA Filing Win?
Revolution Medicines (RVMD) has seen significant stock price appreciation following the FDA's acceptance of its New Drug Application for daraxonrasib. Despite a 137.32% year-to-date increase, Simply Wall St's analysis suggests RVMD is 8.2% undervalued, with a fair value pegged at $204.38 based on its strong pipeline of oncology treatments. However, the company still faces risks associated with high cash burn and the potential for trial delays.
Price to earnings forward of Revolution Medicines, Inc. – BOATS:RVMDW
The article focuses on the "Price to earnings forward" for Revolution Medicines, Inc. (RVMDW), listed on the Blue Ocean Alternative Trade System (BOATS). It presents financial information related to RVMDW, including market status and data provided by ICE Data Services and FactSet. The page indicates that the market was closed with no trades.
Revolution Medicines, Inc. Revenue Breakdown – NASDAQ:RVMD
This page provides financial overview information for Revolution Medicines, Inc. (NASDAQ: RVMD) on TradingView. It indicates that the market is currently closed with no trades and offers access to various financial data points such as statements, statistics, dividends, earnings, and segment performance.
FDA Priority Review For Daraxonrasib Might Change The Case For Investing In Revolution Medicines (RVMD)
Revolution Medicines (RVMD) has received FDA priority review for its New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for metastatic pancreatic cancer. This decision, backed by positive Phase 3 data, is a significant catalyst for the company, potentially reshaping its investment narrative despite ongoing losses and high spending. Investors will be monitoring Q2 2026 earnings for insights into operational expenses versus pipeline progress, with daraxonrasib's success being key to future financial performance.
Sandra Heller Joins Revolution Medicines as Vice President & General Manager, Canada
Revolution Medicines has appointed Sandra Heller as Vice President & General Manager for Canada, enhancing its commercial leadership in oncology. Heller brings over 25 years of experience from companies like Astellas Pharma Canada, Seagen, Gilead Sciences, and Roche, and will lead Canadian operations, commercial strategy, and market expansion. Her appointment underscores Revolution Medicines' commitment to delivering innovative targeted therapies, particularly for RAS-addicted cancers, to patients in Canada.
Enterprise value to EBIT forward of Revolution Medicines, Inc. – NASDAQ:RVMDW
This article focuses on the enterprise value to EBIT forward of Revolution Medicines, Inc. (NASDAQ: RVMDW). The content primarily serves as a financial data point or a placeholder within the TradingView platform for the company's financial metrics.
Revolution Medicines Number of Employees 2026 | Employee Count & Headcount Data
Revolution Medicines, Inc. (NASDAQ: RVMD) had approximately 1,025 employees worldwide as of March 2026, marking an 83.5% growth since 2023. The company is actively hiring, with 384 active job postings in 2026, and its workforce is primarily concentrated in the United States. Employee sentiment is neutral but improving, and the average salary is $216,810.
Revolution Medicines (NASDAQ:RVMD) Flashes Strong Technical Breakout Setup
Revolution Medicines (NASDAQ:RVMD) is showing a strong technical breakout setup, scoring 9 out of 10 on both ChartMill's Technical Rating and Setup Quality Rating. This indicates a sustained positive trend with the stock trading well above its moving averages and near its 52-week high, coupled with a tight consolidation pattern resembling a bull flag. The article suggests RVMD is a textbook candidate for a breakout trade, with potential for a new leg higher if it breaks above the resistance zone around $192.62–$192.63.
